Kenneth C. Anderson, MD
Novel immunotherapeutic strategies will redefine multiple myeloma treatment, but these new approaches must be used in combination if patients are to achieve cures, according to Kenneth C. Anderson, MD, a leading expert in the malignancy who has been at the forefront of research for nearly 30 years.
“In the future, we’re going to do combination therapies. They will be used in a subset of patients better defined by profiling,” Anderson said. “If we’re going to have long-term disease-free survival—cure—we have to get minimal residual disease (MRD) negativity with our targeted therapies, and then we need to restore host immunity. We need to have no disease, and we need to have patients off therapy. Quality of life is just as important as having no disease.”
Anderson provided an overview of emerging developments involving monoclonal antibodies, immunomodulatory drugs (iMiDs), immunotoxins, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies
during a presentation at the Charlotte Plasma Cell Disorder Congress, held in North Carolina in August. He is the program director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute and the Kraft Family Professor of Medicine at Harvard Medical School, both in Boston, and a 2014 Giant of Cancer Care®
award winner in multiple myeloma.
... to read the full story